The semi-annual rebalancing of the SPDR S&P Developed Quality Aristocrats ETF ($QDEV (+0,49 %) ) has just been completed, bringing notable changes to the composition of this quality-focused investment vehicle.

Outgoing Companies:

• RELX PLC$REL (-1,15 %)
• Keyence Corporation $6861 (+0,08 %)
• London Stock Exchange Group plc $LSEG (+0 %)
• Booking Holdings Inc. $BKNG (+0 %)
• Industria de Diseno Textil S.A. (Inditex) $ITX (+1,22 %)
• Texas Instruments Incorporated $TXN (+0,32 %)
• Cencora Inc.$COR (-1,45 %)
• Coloplast A/S Class B$COLO B (+0,71 %)
• Moncler SpA $MONC (+2,28 %)
• Cardinal Health Inc. $CAH (+0,04 %)
• CAR Group Limited $CAR (+1,93 %)
• Waters Corporat $WAT (-0,18 %)
• Nova Ltd. $NVMI (+0,39 %)
• Monolithic Power Systems Inc. $MPWR (+0,2 %)

Incoming Companies:

• Alphabet Inc. Class C$GOOG (-0,16 %)
• Nintendo Co. Ltd.$7974 (-1,35 %)
• S&P Global Inc. $SPGI (+0 %)
• InterContinental Hotels Group PLC $IHG (-0,96 %)
• Bristol-Myers Squibb Company $BMY (+0,46 %)
• Intercontinental Exchange Inc. $ICE (-0,12 %)
• Regeneron Pharmaceuticals Inc. $REGN (+0,59 %)
• Motorola Solutions Inc. $MSI (-0,13 %)
• Marriott International Inc. Class A $MAR (-0,17 %)
• Hilton Worldwide Holdings Inc. $HLT (+0,28 %)
• Industrivarden AB Class C$INDU C (+1,68 %)
• EMS-CHEMIE HOLDING AG$EMSN (+0,99 %)
• D'Ieteren Group SA/NV $DIE (-0,34 %)
• Electronic Arts Inc. $EA (-0,48 %)
• CK Infrastructure Holdings Limited $1038 (+0,71 %)

This rebalancing aligns QDEV with evolving market conditions while maintaining its focus on quality companies with strong financial foundations. For investors seeking exposure to financially robust global corporations, these changes appear strategically sound, particularly with the inclusion of resilient tech giants and hospitality leaders positioned for growth.

Will this prove to be a winning choice? The fundamentals certainly suggest so.

#Investing
#ETF
#QDEV
#PortfolioManagement
#QualityStocks

I’m exiting my position in $CAH (+0,04 %) due to underperformance, likely caused by the non-renewal of the OptumRx contract, which ended in July 2024, as well as deteriorating future prospects.

These include an expected slowdown and declines in both EPS and revenue for 2025.

I am replacing it with $THC (-0,58 %) to maintain sector balance in my portfolio, as I believe this stock has stronger potential due to its relatively low valuation compared to peers, positive momentum, favorable earnings revisions (14 upgrades versus 2 downgrades), solid future growth prospects, and manageable debt levels.

While it’s not exactly in the same industry—Tenet operates surgery centers, ambulatory facilities, laboratories, and pharmacies—it remains within the broader healthcare sector.

I also see this as a potential "buy-the-dip" opportunity, following a 15% decline this past month after a strong bull run that drove the stock price from $53 to $163 over the course of a year.

I feel that is important to mention that I use Seeking Alpha as my source of information. The analysis than can be found there, the financial information and also the quantitative factors that they give to the stocks, have a significant importance on the decisions I make. In this case, $CAH (+0,04 %) had a Strong Buy quant rate when I bought it and now it is classified as a Hold and has been stuck there for months now, meanwhile $THC (-0,58 %) has mantained a Buy or Strong Buy rating for the last few months.

Woke up to this Trans

😱😊

I’m happy with it!!

What do you think? what should I invest in?

$NEP
$CHCT (+0,76 %)
$CWH (-0,31 %)
$CAH (+0,04 %)
$LUV (-0,34 %)

Which of my positions do you think I should make bigger (and why)?

On the following months I'd like to go for:

Airlines: $UAL (+0,31 %) or $IAG (+0,82 %) --> Good momentum, growth ahead, undervalued.

Insurance: $CS (-0,04 %) or $ALV (+0,63 %) --> Good dividend, good momentum, good perspectives, high dividend.

European Banks:
$ISP (+0,56 %) or $CABK (+0,16 %) --> Undervalued Vs American banks, better environment than years ago with lower valuations, higher interest and more security... possibility of gaining stock apretiation while receiving high dividends.

Homebuilding: $LEN (-0,14 %) --> They have a clear problem with lack of homes in the US, good valuation, good growth prospects.

Also tempted to double with my pharma losers $CAH (+0,04 %) and $AMPH (-0,2 %) , bought them when they were with good momentum and they've underperformed since, but I still like the future prospects... High growth, small caps, good drug portfolio... If I still like the numbers and they're cheaper now, should I double my bet here?(I hate going against momentum). $PFE (+0,32 %) also on the list, but I have it on a small saving plan. Shifting momentum but still early to say so I prefer to buy slow...

I'm not planing on adding stocks that are not currently in my portfolio.